Progestin-only contraception and venous thromboembolism.

Assessing the risk of venous thromboembolic events in women taking progestin-only contraception: a meta-analysis

OBJECTIVES To evaluate the risk of venous thromboembolic events associated with the use of progestin-only contraception and whether that risk differs with the mode of drug delivery (oral, intrauterine, or depot injection). DESIGN Systematic review and meta-analysis of randomised controlled trials and observational studies. DATA SOURCES Pubmed, Embase, Cochrane Library, and reference lists o...

Risk of recurrent venous thromboembolism on progestin-only contraception: a cohort study.

Risks of venous thromboembolism with various hormonal contraceptives.

Evidence There are no long-term RCTs, which leaves cohort and case-control studies as evidence. • The Society of Obstetricians and Gynaecologists of Canada1 and others2 have stated that evidence about the risk of VTE with different progestins is inconclusive owing to mixed results and a high risk of bias. • Some studies found no increased VTE risk with drospirenone3 or a transdermal patch.4 • S...

Cancer and contraception

As a result of advances in cancer diagnosis and treatment, young women within the reproductive-aged group are now more likely to survive cancer. Reproductive-aged women with cancer may be interested in deferring pregnancy either temporarily or permanently at cancer diagnosis, during therapy or after treatment. Currently, there are limited guidelines to aide clinicians in managing the contracept...

Thrombotic stroke and myocardial infarction with hormonal contraception.

BACKGROUND Although several studies have assessed the risk of venous thromboembolism with newer hormonal contraception, few have examined thrombotic stroke and myocardial infarction, and results have been conflicting. METHODS In this 15-year Danish historical cohort study, we followed nonpregnant women, 15 to 49 years old, with no history of cardiovascular disease or cancer. Data on use of ho...